Market Research Report
Global Opioid-Induced Constipation Market 2018-2022
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||334065|
|Published||Content info||98 Pages
Delivery time: 1-2 business days
|Global Opioid-Induced Constipation Market 2018-2022|
|Published: December 6, 2018||Content info: 98 Pages||
Rise in incidence of chronic diseases such as arthritis, back pain, and migraine is likely to drive growth in the market. The incidence of chronic pain is increasing across the world, owing to the several reasons, including lifestyle changes, rise in number of injuries, growth in number of surgeries, and painful medical conditions. Technavio's analysts have predicted that the opioid-induced constipation market will register a CAGR of more than 32% by 2022.
Rise in incidences of diseases associated with old age, impaired body functions, and increase in the use of medicines such as antidepressants and anticholinergics have collectively led to high prevalence of constipation among the elderly population. This drives growth in the opioid-induced constipation market.
The use of laxatives for OIC is a major challenge that is reducing sales of approved drugs meant for the treatment of OIC.
For the detailed list of factors that will drive and challenge the growth of the opioid-induced constipation market during the 2018-2022, view our report.
The market appears to be fragmented and with the presence of several companies including Takeda Pharmaceutical and Merck the competitive environment is quite intense. Factors such as the rise in incidence of chronic diseases such as arthritis, back pain, and migraine and the rise in OIC cases among elderly, will provide considerable growth opportunities to opioid-induced constipation manufactures. AstraZeneca, Bausch Health, Takeda Pharmaceutical, and Merck are some of the major companies covered in this report.